Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 10/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | S100A4 | P26447 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | APAF1 | O14727 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 1.00 |
| ▸ | GALK1 | P51570 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | TDP2 | O95551 | 2/20 | 1.00 |
| ▸ | PLA2G1B | P04054 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | PLCG1 | P19174 | 2/20 | 1.00 |
| ▸ | PPARG | P37231 | 2/20 | 1.00 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30043508 | 1.00 | PTPRC (1.00) | PTPRCNPC1RAB9ASMN1; SMN2S100A4 | |
| SCHEMBL30482647 | 0.95 | NPC1 (0.95) | PTPRCNPC1RAB9ASMN1; SMN2S100A4 | |
| SCHEMBL760965 | 0.95 | NPC1 (0.95) | PTPRCNPC1RAB9ASMN1; SMN2S100A4 | |
| SCHEMBL6262683 | 0.95 | PTPRC (1.00) | PTPRCNPC1RAB9ASMN1; SMN2S100A4 | |
| SCHEMBL31615519 | 0.95 | NPC1 (0.95) | PTPRCNPC1RAB9ASMN1; SMN2S100A4 | |
| Anthraquinone SCHEMBL23363689 | 0.93 | NPC1 (1.00) | PTPRCNPC1RAB9ASMN1; SMN2S100A4 | |
| SCHEMBL40960 | 0.93 | NPC1 (1.00) | PTPRCNPC1RAB9ASMN1; SMN2S100A4 | |
| SCHEMBL31290097 | 0.93 | NPC1 (1.00) | PTPRCNPC1RAB9ASMN1; SMN2S100A4 | |
| SCHEMBL1143226 | 0.91 | PTPRC (0.91) | PTPRCNPC1RAB9ASMN1; SMN2S100A4 | |
| Benzene SCHEMBL28832927 | 0.91 | NPC1 (0.95) | PTPRCNPC1RAB9ASMN1; SMN2S100A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023285654-A2 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | DOMPE' FARMACEUTICI SPA (IT) | 2023-01-19 | — | — | WO | claimed |
| EP-4119145-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2023-01-18 | — | — | EP | claimed |
| US-20130090355-A1 | CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-04-11 | — | — | US | claimed |
| WO-2011146101-A1 | CHEMICAL AGENTS FOR THE PREVENTION OR INHIBITION OF TUMOR METASTASIS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2011-11-24 | — | — | WO | claimed |
| US-20030207812-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | claimed |
| JP-2003518085-A | — | — | 2003-06-03 | — | — | JP | claimed |
| EP-1242363-A2 | CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | claimed |
| WO-2001046125-A2 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | claimed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023285654-A2 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | DOMPE' FARMACEUTICI SPA (IT) | 2023-01-19 | — | — | WO | disclosed |
| EP-4119145-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2023-01-18 | — | — | EP | disclosed |
| EP-4119145-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2023-01-18 | — | — | EP | disclosed |
| US-20220001015-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | SEAPORT THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-5858571-A | TREATING A PULVERIZED HYDROGEN ABSORBING ALLOY WITH A SOLUTION COMPRISING A CONJUGATED UNSATURATED COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1999-01-12 | — | — | US | disclosed |
| EP-0872903-A1 | Method for making hydrogen storage alloy powder and electrode comprising the alloy powder | Shin-Etsu Chemical Co., Ltd. (JP) | 1998-10-21 | — | — | EP | disclosed |
| EP-0172427-B1 | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | Shin-Etsu Chemical Co., Ltd. (JP) | 1989-07-05 | — | — | EP | disclosed |
| US-4758639-A | Process for production of vinyl polymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-19 | — | — | US | disclosed |
| US-4757124-A | Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220001015-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | LIPA, MALT1, SGMS1 | PTPRC 163/4885NPC1 57/4885RAB9A 1988/4885 |
| US-20030207812-A1 | Cd45 inhibitors | CD74, CD2, PTPRC | PTPRC 3/4885NPC1 3699/4885RAB9A 1987/4885 |
| US-20130090355-A1 | CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS | S100A4, S100A6, S100A10 | PTPRC 507/4885NPC1 4286/4885RAB9A 1861/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | PTPRC 2412/4885NPC1 23/4885RAB9A 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.